Ustekinumab for treating active psoriatic arthritis

Review proposal consultation

Stakeholder matrix (PDF 40 KB)

Review proposal paper (PDF 290 KB)

Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: equality impact assessment form - guidance development (PDF 170 KB)

Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: final appraisal determination information

Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: final appraisal determination document (PDF 280 KB)

Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: committee papers information

Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: committee papers (PDF 1.02 MB)

Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313): appraisal consultation

Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313): appraisal consultation document (PDF 685 KB)

Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313): committee papers information

Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313): committee papers (PDF 1.82 MB)